Search Results

Displaying Results 101-125 of 473 "'CMC'"

Jun 05, 2026, 10:00 ET Zifo Transforms EHS Policy Management with New AI-Enabled Services Accelerator

accelerator is highly adaptable and fits seamlessly into multiple segments of the scientific value chain, including R&D, Preclinical Development and CMC, Manufacturing, Quality Assurance & Quality Control, Facilities & Operations, and Contract Development and Manufacturing Organizations (CDMOs).Bridging

More news about: Zifo


Jun 04, 2026, 08:30 ET Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day

collaboration models between biotech companies and CDMO partners, drawing on experience from both biotech and biopharma environments. Dr. Yu Zhang, CMC Head of DualityBio, analyzed the trends of the global XDC market, the differentiated competitive landscape of the industry, and the strategic collaboration

More news about: BioDlink Biopharm Co., Ltd.


Jun 04, 2026, 08:00 ET Adlib Appoints Kristen Sauter as President & GM of Life Sciences to Accelerate Its Vertical AI Strategy

underlying data and documents feeding it.Clinical trial records, adverse event reports, regulatory submissions, batch release documentation, and CMC files are among the most complex, high-stakes documents in any enterprise. They are also among the least AI-ready: inconsistently formatted, multi-modal,

More news about: Adlib Software


Jun 03, 2026, 09:23 ET ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

together, we can help our clients move Investigator-Initiated Trials forward with greater speed, confidence, and simplicity."By integrating CMC, non-clinical studies, and clinical operations into one coordinated solution, the collaboration accelerates IIT start-up timelines and enables more efficient

More news about: ProBio Inc.


Jun 03, 2026, 03:39 ET ACROBiosystems, 바이오 코리아 2026에서 GMP 역량 기반의 포괄적인 CGT 솔루션 선보이며 혁신 주도 및 파트너 역량 강화

Therapy, CGT) 개발을 위한 포괄적인 엔드투엔드 솔루션을 선보였다. Resilient Supply™는 성장 인자와 무혈청 배지부터 생분해성 나노마그네틱 비드까지 다양한 GMP 등급 핵심 원자재를 제공하여 다양한 면역세포 및 줄기세포의 효율적인 배양과 분화를 구현한다. CMC 품질 관리를 위해 SAFENSURE™ 안전성 솔루션과 resDetect™ 잔류 검출 솔루션이 글로벌 약전 기준을 충족하도록 개발되어 규제 준수를 보장하고 테스트 효율성을 향상한다. 이 통합적 접근법은 연구에서 상업 생산까지 CGT 개발 전 과정에 걸쳐 혁신을 주도하고

More news about: ACROBiosystems


Jun 02, 2026, 09:10 ET Stramsen Biotech Thanks the FDA for Their Review and Positive Feedback on Pre IND Application for SBX-1977 Wound Care Medicine

indication. The FDA's written responses received on April 21, 2026, indicated that the Company's proposed chemistry, manufacturing and controls (CMC) strategy and nonclinical package appear reasonable to support IND submission and the planned Phase 1 study. The Agency also provided recommendations

More news about: Stramsen Biotech Inc


Jun 02, 2026, 08:00 ET Phosphorex Names John Rigg Chairman of the Board

Phosphorex. The company is now more than 20 years old with an expanding portfolio of capabilities spanning formulation optimization, process design, CMC strategy, and analytical development across LNP, polymeric nanoparticle, and microsphere platforms. Demand for specialized drug delivery expertise is

More news about: Phosphorex LLC


Jun 01, 2026, 08:00 ET Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

as Chief Medical Officer of Full-Life Technologies, where he led global development, regulatory affairs, clinical operations, translational research, CMC, quality assurance, and program management for the company's radiotherapy pipeline. There he led the translation of three targeted radioconjugate compounds

More news about: Actinium Pharmaceuticals, Inc.


Jun 01, 2026, 07:00 ET Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

agreement, hVIVO will support Decoy across translational modeling, regulatory strategy, scientific advice preparation, Chemistry Manufacturing and Controls (CMC) consulting, non-clinical development support, and preparation of key clinical and regulatory documentation required for European and UK clinical trial

More news about: Decoy Therapeutics, Inc


May 31, 2026, 23:51 ET Aphranel® MagiCCrystal CaHA Filler obtient la certification MDR de l'UE en tant qu'injectable régénérateur de première qualité

réglementaire.Le produit de comblement injectable pour le visage à base de CaHA d'Aphranel est composé de 30 % de microsphères de CaHA et de 70 % de gel de CMC servant de support. Le matériau est conçu pour fournir un soutien structurel immédiat et stimuler la régénération du collagène par des mécanismes de

More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel


May 31, 2026, 23:50 ET Aphranel® MagiCCrystal CaHA Filler erhält die EU MDR-Zertifizierung als hochwertiges regeneratives Injektionsmittel

klinische und behördliche Normen validiert wurde.Der injizierbare CaHA-Gesichtsfüller von Aphranel besteht aus 30 % CaHA-Mikrosphären und 70 % CMC-Gelträger. Das Material ist so konzipiert, dass es sofortige strukturelle Unterstützung bietet und die Kollagenregeneration durch biostimulierende Mechanismen

More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel


May 31, 2026, 22:37 ET ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential

needs in oncology and immunology, by powering a proprietary technology triad: Ori®Ab (antibody discovery), Ori®Armoring (T-cell enhancement), and OnGo CMC (rapid manufacturing), Oricell has successfully established a robust pipeline targeting both solid and hematological tumors. The company's clinical translation

More news about: Oricell Therapeutics Holdings Limited


May 29, 2026, 02:28 ET Aphranel® MagiCCrystal obtiene la certificación EU MDR

y regulatorio.El relleno facial inyectable de CaHA de Aphranel está formulado con un 30 % de microesferas de CaHA y un 70% de gel portador de CMC. El material está diseñado para proporcionar soporte estructural inmediato y estimular la regeneración de colágeno a través de mecanismos bioestimulantes.Entre

More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel


May 28, 2026, 10:00 ET Zifo Unifies Disconnected Lab Systems with AI-Enabled Data Orchestration

workflow engines, and intelligent AI guidance systems, Zifo ensures digital and data continuity is maintained from the earliest stages of R&D, through CMC, Quality Control, and into Manufacturing.Zifo's approach is more than just a technical exercise of linking systems; it is a strategic enabler

More news about: Zifo


May 28, 2026, 09:00 ET China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy

China-US dual filing strategy of innovative drugs.As the exclusive CDMO partner for the project, Porton Advanced provided comprehensive bacteria CMC services, including strain construction, process development, GMP production, quality studies, release testing, and regulatory submission support. Utilizing

More news about: Porton Advanced


May 28, 2026, 07:08 ET China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy

a new chapter in global clinical development. As the exclusive CDMO partner for the project, Porton Advanced provided comprehensive bacteria CMC services, including strain construction, process development, GMP production, quality studies, release testing, and regulatory submission support. Utilizing

More news about: Porton Advanced


May 28, 2026, 06:00 ET HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions

advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies. For more information, please visit: https://www.HanchorBio.com

More news about: HanchorBio Inc.


May 28, 2026, 04:21 ET Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable

through clinical and regulatory compliance standards.Aphranel's CaHA injectable facial filler is formulated with 30% CaHA microspheres and 70% CMC gel carrier. The material is designed to provide immediate structural support and stimulate collagen regeneration through biostimulatory mechanisms.Its

More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel


May 28, 2026, 03:55 ET Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable

through clinical and regulatory compliance standards.Aphranel's CaHA injectable facial filler is formulated with 30% CaHA microspheres and 70% CMC gel carrier. The material is designed to provide immediate structural support and stimulate collagen regeneration through biostimulatory mechanisms.Its

More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel


May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC

bispecific antibody portfolios.We have established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of our drug candidates, coupled with our global perspectives, proactive strategy,

More news about: Nanjing Leads Biolabs Co., Ltd.


May 27, 2026, 08:00 ET From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery

enablement, protein construct quality, target modulation, in vivo efficacy, therapeutic index, scaffold-specific toxicity, DDI risk, cross-species PK, early CMC considerations, and nomination criteria can all influence program decisions.In this context, integration is less about placing multiple capabilities

More news about: Viva Biotech


May 27, 2026, 08:00 ET From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery

enablement, protein construct quality, target modulation, in vivo efficacy, therapeutic index, scaffold-specific toxicity, DDI risk, cross-species PK, early CMC considerations, and nomination criteria can all influence program decisions.In this context, integration is less about placing multiple capabilities

More news about: Viva Biotech


May 27, 2026, 06:45 ET CMC to Host 2026 Investor Day on August 5, 2026

CMC Investor Day 2026. A replay of the webcast and accompanying materials will be available following the event.About CMCCMC is a Fortune 500 company (NYSE: CMC) headquartered in Irving, Texas, and a leading provider

More news about: CMC


May 26, 2026, 16:15 ET CMC Announces Third Quarter Fiscal 2026 Conference Call Webcast Details

www.cmc.com. About CMCCMC is a Fortune 500 company (NYSE: CMC) headquartered in Irving, Texas, and a leading provider of early-stage construction solutions that support the foundational phases of modern infrastructure and building projects. Founded in 1915, CMC has grown from a single-site

More news about: CMC


May 26, 2026, 04:00 ET HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29

advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies. For more information, please visit: https://www.HanchorBio.com

More news about: HanchorBio Inc.


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.